Drug Discovery Program- Shenzhen, China

009

Shenzhen * ChinaBIT's 9th Annual Congress of International Drug Discovery Science and Technology

Program

Time: November 3-6, 2011Venue: Shenzhen Convention & Exhibition Center (SCEC), China

RegistrationTime: 08:30-18:00, November 2, 2011 (Wednesday) Place: Room No. 205, 2nd Floor, SCEC

Group PhotoTime: 08:20-08:40, November 3, 2011 (Thursday) Place: Outside Square, SCEC

Opening Ceremony and Keynote Forum

Opening CeremonyTime: 09:00-09:20, November 3, 2011 (Thursday) Place: Osmanthus Hall, 6th Floor, SCEC

Keynote ForumTime: 09:20-11:50, November 3, 2011 (Thursday) Place: Osmanthus Hall, 6th Floor, SCEC

Moderator Dr. Zhong Zhong, Senior Director of Discovery Technology, GlaxoSmithKline RD, China

09:20-09:45 Title: From the Structure of the Ribosome to New AntibioticsDr. Thomas A. Steitz, The Nobel Prize Laureate in Chemistry 2009; Sterling Professor of MolecularBiophysics and Biochemistry, Yale University, USA

09:45-01:10 Title: Form Basic Science to Improved AntibioticsDr. Ada E.Yonath, The Nobel Prize Laureate in Chemistry 2009; Director of the Helen and MiltonA. Kimmelman Center for Biomolecular Structure and Assembly, Weizmann Institute of Science, Israel

10:10-10:35 Title: The Ubiquitin-proteasome System: From Basic Research to Drug DiscoveryDr. Avram Hershko, The Nobel Prize Laureate in Chemistry 2004; Professor, Technion – Israel Institute of Technology, Israel

10:35-11:00 Title: From Dream to Reality in Less Than 10 YearsDr. Rolf G. Werner, Senior Vice President, Corporate Division Biopharmace, Boehringer IngelheimGmbh, Germany

11:00-11:25 Title: Targeting RANKL Pathway for Drug Discovery and DevelopmentDr. Scott Simonet, Vice President, Metabolic Disorders Therapeutic Area, Amgen, USA

11:25-11:50 Title: Innovation by Novel and Established Drug TargetsDr. Khusru Asadullah, Head of Global Biomarker, Bayer HealthCare Pharmaceuticals, Bayer PharmaAG, Germany

Chapter 1: Drug Discovery Biology

Session 1-1: Systems Biology in Drug DiscoveryTime: 13:30-15:10, November 3, 2011 (Thursday) Place: Chrysanthemum Hall, 5th Floor, SCEC

Session Chair Dr. Ting-Chao Chou, Director, Preclinical Pharmacology Core, Molecular Pharmacology & ChemistryProgram, Memorial Sloan-Kettering Cancer Center, USA

010


13:30-13:55 Title: Simulation, Imaging and Animal Models for Locoregional Therapeutic RadiopharmaceuticalsDevelopmentDr. Franklin Chiu-Leung Wong, Professor of Nuclear Medicine and Neuro-Oncology, Universityof Texas M.D. Anderson Cancer Center, USA

13:55-14:20 Title: The Mass-Action Law Based Algorithms for Efficient Drug Discovery and Drug DevelopmentDr. Ting-Chao Chou, Director, Preclinical Pharmacology Core, Molecular Pharmacology & ChemistryProgram, Memorial Sloan-Kettering Cancer Center, USA

14:20-14:45 Title: G6PD-deficient Cells as Models to Study PharmacometabolomicsDr. Daniel Tsun-Yee Chiu, Professor and Dean of Research & Development, Chang Gung University,Taiwan

14:45-15:10 Title: Systematic Profiling of the Signal Transduction Network in Rheumatoid ArthritisDr. Rob Yang, Postdoc Fellow, Department of Systems Biology, Harvard Medical School, USA

Session 1-2: Structural Biology and Drug DiscoveryTime: 13:30-15:35, November 3, 2011 (Thursday) Place: Rose 1 Hall, 5th Floor, SCEC

Session Chair Dr. Michael Hennig, Vice Director & Head, Discovery Technologies, F. Hoffmann-La Roche Ltd.,Switzerland

13:30-13:55 Title: Drug Discovery Facilitated by Screening & Biophysical MethodsDr. Michael Hennig, Vice Director & Head, Discovery Technologies, F. Hoffmann-La Roche Ltd.,Switzerland

13:55-14:20 Title: Crystal Structure of the Acid-activated Urea Channel from the Human Pathogen HelicobacterPyloriDr. Hartmut Luecke, Director, Center for Biomembrane Systems, Department of Biochemistry, Biophysics & Computer Science, University of California, USA

14:20-14:45 Title: The Design and Synthesis of Drugs Based on Self-Organizing Quasi-Live SystemsDr. Sonya Sophya Farber, Chief Communications Officer, Noigel, Inc., USA

14:45-15:10 Title: GA-Modified Polymers for Liver Targeting Drug DeliveryDr. Zhi Yuan, Vice Dean, Institute of Polymer Chemistry, Nankai University, China

15:10-15:35 Title: Use of Targeted Library for Efficient Identification of Fragments to Start Medicinal ChemistryDr. Takaaki Miura, Group Leader, Biostructure Research Group, Discovery Research Department,Chugai Pharmaceutical Co., Ltd., Japan

Session 1-3: Oncology and Drug DiscoveryTime: 13:30-17:10, November 3, 2011 (Thursday) Place: Peony Hall, 5th Floor, SCEC

Session Chair Dr. Rob Howes, R & D Director, Horizon Discovery, UKCo-Chair Dr. Xiaoyan Jiang, Senior Scientist, Terry Fox Laboratory, BC Cancer Research Centre, Canada

13:30-13:55 Title: Development of Antibody-based Therapies for CancerDr. Steve Coats, Director of Oncology Research, MedImmune, USA

13:55-14:20 Title: Human ‘Knock-In’ and ‘Kock-Out’ Cell-Lines for Precision Functional Genomics and TargetedDrug DiscoveryDr. Rob Howes, R & D Director, Horizon Discovery, UK

14:20-14:45 Title: New Marine Anticancer Agents and Their Mechanisms of ActionDr. Hendrik Luesch, Associate Professor, Department of Medicinal Chemistry, University of Florida,USA

011


14:45-15:10 Title: Targeting Lipid Signal Required for Cell Cycle Re-entry by Quiescent Cancer CellsDr. Qihan Dong, Associate Professor, School of Biomedical and Health Sciences, The University of Western Sydney, Australia

15:10-15:30 Coffee Break

15:30-15:55 Title: A Novel Approach to Target an AHI-1-BCR-ABL-JAK2 Interaction Complex in Leukemic StemCellsDr. Xiaoyan Jiang, Senior Scientist, Terry Fox Laboratory, BC Cancer Research Centre, Canada

15:55-16:20 Title: 99mTc-MDP Bone Scan as a Molecular Imaging Technique for Diagnostic Studying in Parathyroid tumors, HPT Metabolic Bone Disease and Related Orthopedic DisordersDr. Jing jing Pen, Professor, Beijing Ji Shui-Tan Hospital, The 4th Clinical Hospital of Peking University, China

16:20-16:45 Title: Do Statins Prevent Oesophageal Cancer? – Evidence from Epidemiology and Its Potential Clinical ImplicationsDr. Andrew R. Hart, Senior Lecturer in Gastroenterology, The University of East Anglia, UK

16:45-17:10 Title: Design and Synthesis of Modified Resveratrol AnaloguesDr. Thet H THET, Lecturer, Jeffrey Cheah School of Medicine and Health Sciences, Monash University (Sunway Campus), Malaysia

Session 1-4: Neurosciences and Drug DiscoveryTime: 15:30-17:35, November 3, 2011 (Thursday) Place: Chrysanthemum Hall, 5th Floor, SCEC

Session Chair Dr. Pierre A. Guertin, Associate Professor, Laval University, Canada

15:30-15:55 Title: Carbon Nanotubes: Promising Nanovectors for Targeted Intracellular Drug DeliveryDr. Silvana Fiorito, Professor, Department of Clinical Medicine, “Sapienza” University of Rome, Italy

15:55-16:20 Title: Cortical Oscillations in Animal Models of SchizophreniaDr. Bernat Kocsis, Associate Professor of Psychiatry, Harvard Medical School, USA

16:20-16:45 Title: Translational Research Strategies in Drug Development for Neurodegenerative DisordersDr. Piu Chan, President and CEO, Wincon TheraCells Biotechnologies Co., Ltd., China

16:45-17:10 Title: Rationale behind the Development of Combination Products in NeurologyDr. Pierre A. Guertin, Associate Professor, Laval University, Canada

17:10-17:35 Title: Early Lesion of The Medial Dorsal Nucleus of the Thalamus Leads to Alterations in Cell Density in the Dentate Gyrus: Possible Animal Model for SchizophreniaDr. Liesl B. Jones, Biological Sciences and Associate Professor, Lehman College, USA

Session 1-5: Molecular Biology and Drug DiscoveryTime: 13:30-16:20, November 3, 2011 (Thursday) Place: Rose 2 Hall, 5th Floor, SCEC

Session Chair Dr. Donna Seto-Young, Director of Endocrinology Laboratory, The Friedman Diabetes Institute, Division of Endocrinology, Department of Medicine, Beth Israel Medical Center and Albert EinsteinCollege of Medicine, USA

13:30-13:55 Title: Thiazolidinediones Affect Bone Biomarkers and Osteoblast Growth Independently of Their Effects on AromataseDr. Donna Seto-Young, Director of Endocrinology Laboratory, The Friedman Diabetes Institute, Division of Endocrinology, Department of Medicine, Beth Israel Medical Center and Albert EinsteinCollege of Medicine, USA

012


13:55-14:20 Title: Chain Reaction of Conformational Changes of Ribosomal RNAs and tRNAs Leading to Accuracyin TranslationDr. Kozo Nagano, Professor and Director, Nagano Research Institute of Molecular Biology, Japan

14:20-14:45 Title: How to Use Large Scale Sequence Data from NGS to Understand Genetics and BiologyDr. Kazuho Ikeo, Professor, Center for Information Biology, National Institute of Genetics, Japan

14:45-15:10 Title: The Luminal Environment and Glucose Behavior in the Small IntestineDr. Toru Takahashi, Associate Professor, Department of Nutrition and Health Science, Faculty of Human Environmental Sciences, Fukuoka Women’s University, Japan


15:30-15:55 Title: MRP1-Targeting Therapy as a New Strategy for Eradication of Resistant Cancer Cells Overexpressing the Multidrug Drug TransporterDr. Helene Baubichon-Cortay, Assistant Professor, Institute of Biology and Chemistry of Proteins(IBCP), Team Drug Resistance Mechanism and Modulation, UMR 5086 CNRS - University Lyon 1, France

15:55-16:20 Title: Polyadenylation as a Therapeutic TargetDr. Cornelia H. de Moor, Lecturer, RNA Biology, School of Pharmacy, University of Nottingham,UK

Session 1-6: Cell Biology and Drug DiscoveryTime: 13:30-16:20, November 3, 2011 (Thursday) Place: Rose 3 Hall, 5th Floor, SCEC

Session Chair Dr. Michael R. Briggs, Senior Director, Biology, Vertex Pharmaceuticals, Inc., USA

13:30-13:55 Title: From the Patient to the Bench to the Patient, A Tumor’S TaleDr. Michael R. Briggs, Senior Director, Biology, Vertex Pharmaceuticals, Inc., USA

13:55-14:20 Title: FreezFect Cells - HT Nucleofector™ Ready Frozen Primary Cells for HTS/HCS ApplicationsDr. Konstantin Matentzoglu, Managing Director; External Group Leader, Department of Biology,Trenzyme GmbH, Germany

14:20-14:45 Title: Induction of Neural Differentiation of Mammalian Adipogenic Stem Cells (ASCs), and the Cell Behavior after Transplantation into Mouse BrainDr. Galina Pavlova, Head, Group of Developmental Genetics and Neurogenetics, Institute of GeneBiology, Russia

14:45-15:10 Title: New Strategies to Tackle Necrotic Cell DeathDr. Ilana Nathan, Associate Professor, Ben-Gurion University and Soroka University Medical Center, Israel


15:30-15:55 Title: Phoretic Motions of BioparticlesDr. Po-Yuan Chen, Assistant Professor, Department of Biological Science and Technology, ChinaMedical University, Taiwan

15:55-16:20 Title: Characterisation of the Molecular Targets in Leptin-Mediated Renal Tubule SignallingDr. Andrew J. McAinch, Senior Lecturer Nutrition, Biomedical and Lifestyle Diseases (BioLED) Unit, School of Biomedical and Health Sciences, Victoria University, Australia

013


Session 1-7: Immunology and Drug DiscoveryTime: 15:55-17:10, November 3, 2011 (Thursday) Place: Rose 1 Hall, 5th Floor, SCEC

Session Chair Dr. Sandeep Mukherjee, Associate Professor, Division of Gastroenterology and Hepatology, University of Nebraska Medical Center, USA

15:55-16:20 Title: Novojoint - Smart Cartilage Transplants with Regenerative and Anti-inflammatory ActivityDr. Michael F.G. Schmidt, Professor and Chairman, Institute of Immunology and Molecular Biology,Freie University in Berlin, Germany

16:20-16:45 Title: Treatment of Hepatitis C after Liver TransplantationDr. Sandeep Mukherjee, Associate Professor, Division of Gastroenterology and Hepatology, University of Nebraska Medical Center, USA

16:45-17:10 Title: Host-pathogen Interaction in Screening for Natural Products with Anti-Infective ActivityDr. Tengku Sifzizul Tengku Muhammad, Dean, Faculty of Science and Technology, University Malaysia Terengganu, Malaysia

Session 1-8: Endocrinology and Drug DiscoveryTime: 13:30-15:10, November 3, 2011 (Thursday) Place: Room No. 316, 3rd Floor, SCEC

Session Chair Dr. Juergen Engel, President & CEO, AEterna Zentaris, GermanyCo-Chair Dr. Hua Zhu (David) Ke, Scientific Executive Director, Metabolic Disorders Research, Amgen Inc.,

USA

13:30-13:55 Title: LHRH Receptors as Targets for Drug Development in CancerDr. Juergen Engel, President & CEO, AEterna Zentaris, Germany

13:55-14:20 Title: Development of Novel Drug, Selective Androgen Receptor Modulator (SARM42) with MetabolicEffect, but no Effect on ProstateDr. Hajime Nawata, President and Director, Fukuoka Prefectural University, Japan

14:20-14:45 Title: Targeting Wnt Signaling in Drug Discovery for Skeletal DiseasesDr. Hua Zhu (David) Ke, Scientific Executive Director, Metabolic Disorders Research, Amgen Inc.,USA

14:45-15:10 Title: Stress Release Aldosterone Modulation: Aiming More Than One TargetDr. Milan Radovic, Associate Professor of Internal Medicine, School of Medicine, University of Belgrade, Serbia

Session 1-9: Microbiology, Virology and Drug DiscoveryTime: 13:30-14:45, November 3, 2011 (Thursday) Place: Room No. 314, 3rd Floor, SCEC

Session Chair Dr. Jonathan Wong, Defence Scientist, Defence Research and Development Canada Suffield, Canada

13:30-13:55 Title: Development of a Novel “Intracellular Immunization” Strategy to Restrict HIV-1 Infection and DisseminationDr. Xiaojian Yao, Associate Professor and MMSF Professor, Director, Laboratory of Molecular Human Retrovirology, Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Canada

13:55-14:20 Title: Toll-like Receptor Agonists as Broad-spectrum Antivirals Against Respiratory VirusesDr. Jonathan Wong, Defence Scientist, Defence Research and Development Canada Suffield, Canada

014


14:20-14:45 Title: In Vitro HIV-1 Selective Integration into the Target Sequence and Decoy-Effect of the ModifiedSequenceDr. Tatsuaki Tsuruyama, Associate Professor, Graduate School of Medicine, Kyoto University, Japan

Session 1-10: Toxicology and Pathology in Drug DiscoveryTime: 15:05-17:10, November 3, 2011 (Thursday) Place: Room No. 314, 3rd Floor, SCEC

Session Chair Dr. Sachin S. Devi, Director, Laboratory of Experimental and Clinical Toxicology; Assistant Professor of Pharmacology, School of Pharmacy, Lake Erie College of Osteopathic Medicine, USA

15:05-15:30 Title: Drugs & Environment – EcopharmacovigilanceDr. Giampaolo Velo, Professor and Director, Clinical Pharmacology Unit, Veneto Region Pharmacovigilance Centre, Reference Centre for Education and Communication within the WHO Programme for International Drug Monitoring, Italy

15:30-15:55 Title: Lessons from Autoprotection Model to Treat Acute Liver FailureDr. Sachin S. Devi, Director, Laboratory of Experimental and Clinical Toxicology; Assistant Professorof Pharmacology, School of Pharmacy, Lake Erie College of Osteopathic Medicine, USA

15:55-16:20 Title: Toxicology and Improving Drug Development; A Discussion on Extractables and LeachablesDr. Tamara Fridman, CEO, Vanasyl LLC., USA

16:20-16:45 Title: Detoxification of Organochlorine Compounds by Non-absorbable Dietary FatDr. Patrick Tso, Professor, Department of Pathology and Laboratory Medicine, University of Cincinnati, USA

16:45-17:10 Title: Drug Discovery and Personalized Medecine in Cystic Fibrosis and other Misfolding DiseasesDr. Frederic Becq, Professor of Physiology; Director of the Institute of Cellular Physiology and Biology, CNRS/University of Poitiers, France

Session 1-11: Epidemiology and Biostatistics for Drug DiscoveryTime: 15:30-17:35, November 3, 2011 (Thursday) Place: Room No. 316, 3rd Floor, SCEC

Session Chair Dr. Jerzy E Tyczynski, Director, Epidemiology, Global Surveillance & Pharmacoepidemiology, Global Medical Services, Global Pharmaceutical R & D, Abbott Laboratories, USA

15:30-15:55 Title: The Role of Epidemiology in Evaluating Safety Issues throughout the Drug Development ProcessDr. Paul Beninger, Vice President, Global Patient Safety, Genzyme, USA

15:55-16:20 Title: Pharmacoepidemiology Observational Studies in Supporting Patient Safety: Focus on OncologyTherapeutic AreaDr. Jerzy E Tyczynski, Director, Epidemiology, Global Surveillance & Pharmacoepidemiology, Global Medical Services, Global Pharmaceutical R & D, Abbott Laboratories, USA

16:20-16:45 Title: Translating the New Discovery into a Clinical and Commercial Success in the New Health –the Statistical ContributionDr. Jorgen Seldrup, Senior Director, Centre for Statistics in Drug Development, Quintiles, France

16:45-17:10 Title: Statistical Modeling of Vaccine SafetyDr. Jie Chen, Head of Statistics, Merck Serono, China

17:10-17:35 Title: Clinical Significance in Statistical Hypothesis Testing: A Regulatory Point of ViewDr. Chenguang Wang, Assistant Professor, Johns Hopkins University, USA

015


Session 1-12: Pharmacology and Drug DiscoveryTime: 13:30-16:45, November 4, 2011 (Friday) Place: Room No. 1, 1st Floor, SCEC

Session Chair Dr. Parviz Ghahramani, Executive Director; Head of Clinical Pharmacology, Forest Research Institute, USA

13:30-13:55 Title: Early Clinical Discovery in Asia: Challenges and OpportunitiesDr. Vincenzo Teneggi, Head of Early Development & Clinical Pharmacology for China and Asia Pacific, pharma Research & Early Development (pRED) China, Roche R & D Center (China) Ltd,China

13:55-14:20 Title: Strategies for Determining Optimal Dosing Regimen for Patients on DialysisDr. Parviz Ghahramani, Executive Director; Head of Clinical Pharmacology, Forest Research Institute, USA

14:20-14:45 Title: In Vitro Approaches to Predict Human Adverse Drug EffectsDr. Albert P. Li, President and CEO, In Vitro ADMET Laboratories LLC, USA

14:45-15:10 Title: Cell-based Assay for Drug Research and Development – A Biopharmaceutic ApproachDr. Dongzhou (Jeffery) Liu, Medical Lead and Principle Clinical Investigator, Medical Affairs andClinical Development, GlaxoSmithKline, USA


15:30-15:55 Title: New Pharmacology and Drug Discovery Leading the World, Combination Drug for DehydratedAtrophy and Eliminating LesionsDr. Tam Kuok Leong, Leader, Medicine Multidisciplinary Inventor, New Pfiyer Medicine Studyingand Developing International Limited, Macao, China

15:55-16:20 Title: Old Drug, New Use: The Beneficial Effect of Beta-Agonist on Sepsis TherapyDr. Wen-Jinn Liaw, Professor and Chairman, Department of Anesthesiology, Tri-Service General Hospital, National Defense Medical Center, Taiwan

16:20-16:45 Title: Nebulized Lidocaine Prevents Airway Inflammation, Peribronchial Fibrosis, and Mucus Production in a Murine Model of AsthmaDr. Marco Martins, Head of the Laboratory of Inflammation, Oswaldo Cruz Institute, FIOCRUZ, Brazil

Chapter 2: Drug Target Discovery and Validation

Session 2-1: Seeking Novel Drug Targets and TrendTime: 08:30-10:10, November 4, 2011 (Friday) Place: Room No. 1, 1st Floor, SCEC

Session Chair Dr. Wei Chen, Professor, Department of Pediatrics, University of Minnesota, USA

08:30-08:55 Title: Dopamine D3 Receptor Antagonists as Novel and Effective Anti-Addiction MedicationsDr. Eliot Lawrence Gardner, Chief, Neuropsychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, USA

08:55-09:20 Title: Toll-like Receptors Targeted Therapy of Hematological MalignanciesDr. Wei Chen, Professor, Department of Pediatrics, University of Minnesota, USA

09:20-09:45 Title: State of the Art of Photodynamic Therapy (PDT); Impact on Medicine and Medical Economics:PDT Emerges from the ShadowDr. Herwig Kostron, Associate Professor for Neurosurgery, Department Neurosurgery, Medical University Innsbruck, Austria

016


09:45-10:10 Title: Jak/Stat1 Pathway as a Target for Tumor Radio and ChemosensitizationDr. Nikolai N. Khodarev, Research Associate Professor, Department of Radiation Cellular Oncology,University of Chicago, USA

Session 2-2: Animal Models as the Tool for Target ValidationTime: 10:30-11:20, November 4, 2011 (Friday) Place: Room No. 1, 1st Floor, SCEC

Session Chair Dr. Boguslaw Tomanek, Professor and Senior Research Officer, University of Calgary, National Research Council of Canada, Canada

10:30-10:55 Title: Application of Molecular IR and MR Imaging Techniques for Testing of Drug EfficacyDr. Boguslaw Tomanek, Professor and Senior Research Officer, University of Calgary, National Research Council of Canada, Canada

10:55-11:20 Title: Animal Models for Antidepressants: Future DirectionsDr. Franco Borsini, Head, Central & Peripheral Nervous System and General, Italy

Session 2-3: GPCRs as Effective Drug TargetsTime: 08:30-11:20, November 4, 2011 (Friday) Place: Room No. 2, 1st Floor, SCEC

Session Chair Dr. Huailing Zhong, President, U-Pharm Laboratories LLC, USACo-Chair Dr. Olaf Schroeder, Managing Director, NeuroProof GmbH, Germany

08:30-08:55 Title: Label-free Cell-based Assays for Drug DiscoveryDr. Ye Fang, Senior Research Manager, Biochemical Technologies, Science and Technology Division,Corning Incorporated, USA

08:55-09:20 Title: Targeting mGlu2/3 Receptors by Allosteric Modulation for CNS DisordersDr. Huailing Zhong, President, U-Pharm Laboratories LLC, USA

09:20-09:45 Title: Cyclic Urea as CCR5 AntagonistsDr. Maosheng Duan, VP and Head of Medicinal Chemistry, HD Biosciences (China) Co., Ltd, China

09:45-10:10 Title: Functional Cell Culture Assays in CNS Drug DevelopmentDr. Schroeder Olaf, Managing Director, NeuroProof GmbH, Germany


10:30-10:55 Title: Adrenomedullin and Adrenomedullin Receptor as a Target for Uterine Contraction Inhibitorduring PregnancyDr. Toshihiko Yanagita, Associate Professor, Department of Pharmacology, Miyazaki Medical College, University of Miyazaki, Japan

10:55-11:20 Title: Genome Driven Target Identification, An Orphan GPCR ApproachDr. Changlu Liu, Research Fellow, Johnson & Johnson Pharmaceutical Research & Development,LLC, USA

Session 2-4: Apoptotic TargetsTime: 08:30-09:45, November 4, 2011 (Friday) Place: Room No. 3, 1st Floor, SCEC

Session Chair Dr. W. Gibson Wood, Professor; Director of Graduate Studies, Department of Pharmacology, University of Minnesota School of Medicine, USA

017


08:30-08:55 Title: Statins and Transcriptional Upregulation of the Major Anti-Apoptotic Protein Bcl-2Dr. W. Gibson Wood, Professor; Director of Graduate Studies, Department of Pharmacology, University of Minnesota School of Medicine, USA

08:55-09:20 Title: Enhancing Paclitaxel-induced Cancer Cell Killing by Antagonizing Bcl-Xl with Navitoclax (ABT-263)Dr. Jue Shi, Assistant Professor, Center for Quantitative Systems Biology, Department of Physics,Hong Kong Baptist University, Hong Kong, China

09:20-09:45 Title: Chemopreventive Effects of Phytochemical Agents on Human Colon Tumor Cells and in a Rat Model of Colon CarcinogenesisDr. Bousserouel Souad, Researcher, INSERM, Laboratory of Nutritional Cancer Prevention, Facultyof Medicine, University of Strasbourg, France

Session 2-5: Protein Kinase Inhibitors and Protein-Protein Interactions as Drug TargetsTime: 10:30-11:20, November 4, 2011 (Friday) Place: Room No. 3, 1st Floor, SCEC

Session Chair Dr. Li Niu, Professor; In-coming Chair, Chemistry Department, The RNA Institute and the Center for Neuroscience Research, State University of New York (SUNY) at Albany, USA

10:30-10:55 Title: Developing RNA Aptamers Against Glutamate Ion ChannelsDr. Li Niu, Professor; In-coming Chair, Chemistry Department, The RNA Institute and the Center for Neuroscience Research, State University of New York (SUNY) at Albany, USA

10:55-11:20 Title: Drugs Against Viral Channel Forming ProteinsDr. Wolfgang B. Fischer, Professor, Institute of Biophotonics, School of Biomedical Science and Engineering, National Yang-Ming University, Taiwan

Chapter 3: Drug Screening Technology

Session 3-1: Quality and Diversity of Libraries of Small-Molecule CompoundsTime: 08:30-09:45, November 4, 2011 (Friday) Place: Room No. 4, 1st Floor, SCEC

Session Chair Dr. Alexander Volker Mayweg, Head of Discovery Chemistry & Metabolic Chemistry Section; Headof Global Library Workgroup, Roche R & D Center (China) Ltd., China

Co-Chair Dr. Zbigniew Pietrzkowski, CSO, Applied BioClinical Inc., USA

08:30-08:55 Title: Quality Diverse Compound Libraries – Are We There yet and Where are We Going: A RochePerspectiveDr. Alexander Volker Mayweg, Head of Discovery Chemistry & Metabolic Chemistry Section; Headof Global Library Workgroup, Roche R & D Center (China) Ltd., China

08:55-09:20 Title: Screening of Natural Products in Human Relevant Systems (HRS)Dr. Zbigniew Pietrzkowski, CSO, Applied BioClinical Inc., USA

09:20-09:45 Title: Quality Control on Tcm Information for Drug DevelopmentDr. William Wei-guo Jia, VP (Research), Shanghai Innovative Research Center of Traditional Chinese, China

Session 3-2: High-throughput Screening and High-Content Screening in Drug DiscoveryTime: 08:30-11:45, November 4, 2011 (Friday) Place: Room No. 5, 1st Floor, SCEC

Session Chair Dr. Frank Yan, Associate Director; Head of Molecular Design and Biostructure, Deputy Head of Discovery Information, Roche Pharma Research and Early Development China, China

018


08:30-08:55 Title: Screening an Ion Channel Library for Safe and Effective Drugs: From HTS to ClinicDr. Arthur M. "Buzz" Brown, Executive Chairman & CSO, ChanTest Corporation, USA

08:55-09:20 Title: OPI: A Novel Approach for High-throughput Screening Primary Hit SelectionDr. Frank Yan, Associate Director; Head of Molecular Design and Biostructure; Deputy Head of Discovery Information, Roche Pharma Research and Early Development China, China

09:20-09:45 Title: A Time-resolved Biosensor for Drug ScreeningDr. Masahide Terazima, Professor, Department of Chemistry, Graduate School of Science, Kyoto University, Japan

09:45-10:10 Title: Comprehensive Multi-omics high-throughput Solutions for Drug R & DDr. Na Liu, Director, Department of Pharmacogenomics R & D, The Beijing Genomics Institute, China


10:30-10:55 Title: Advanced Discovery Platforms with BacMam Mediated Cellular AssaysDr. Timothy Wong, Market Development Manager, Drug Discovery, Pharma & CRO, Life Technologies,USA

10:55-11:20 Title: Real Time Cell Surface Interaction Analysis: A Focus on Lectin-Cell Glycan InteractionsDr. Zhichao Pei, Professor, College of Science, Northwest A&F University, China

11:20-11:45 Title: Expediting Kinetic Characterization, Epitope Binning and Epitope Mapping of Antibodies Using Label-free BiosensorsDr. Yasmina Abdiche, Associate Research Fellow, Protein Engineering Department, Rinat-Pfizer, USA

Session 3-3: Tissue-based Drug ScreeningTime: 10:30-11:45, November 4, 2011 (Friday) Place: Room No. 4, 1st Floor, SCEC

Session Chair Dr. Zhanfeng Cui, Scientific Founder, Zyoxel Ltd., UK

10:30-10:55 Title: 3D Perfused Tissue Culture: A Platform for Acute and Chronic Drug TestingDr. Zhanfeng Cui, Scientific Founder, Zyoxel Ltd., UK

10:55-11:20 Title: Coupling Amperometry and Total Internal Reflection Fluorescence Microscopy for MonitoringExocytosis of Single VesiclesDr. Christian Amatore, Director of the Research Unit “PASTEUR”; CNS Full Professor, CNRS, ENS and UPMC, France

11:20-11:45 Title: The Use of a Long Shelf-life in vitro Cell Model of the Human Airway Epithelium (MucilAir™)in Preclinical Drug DevelopmentDr. Samuel Constant, Chief Operating Officer, Epithelix Sàrl, Switzerland

Chapter 4: Rational Drug Design

Session 4-1: New Computer-Aided Drug DesignTime: 08:30-10:10, November 4, 2011 (Friday) Place: Room No. 6, 1st Floor, SCEC

Session Chair Dr. Jianxin Duan, Senior Applications Scientist, Schrödinger GmbH, Germany

08:30-08:55 Title: Using Semi-Continuum Theory to Aid Drug Discovery and OptimizationDr. Anthony Nicholls, CEO, OpenEye Scientific Software, Inc., USA

019


08:55-09:20 Title: Understanding Ligand Binding Affinity and Specificity through Analysis of Hydration Site ThermodynamicsDr. Jianxin Duan, Senior Applications Scientist, Schrödinger GmbH, Germany

09:20-09:45 Title: Computational Drug-Design Based on the Spatial Structures of the Targeting Proteins Derivedfrom Some SubtypesDr. Jishou Ruan, Professor of Mathematics and Chair, Department of Probability and InformationTheory, College of Mathematical Sciences, University of Nankai, China

09:45-10:10 Title: Role of Waters in Ligand BindingDr. Art E. Cho, Professor and Chairman, Department of Biotechnology and Bioinformatics, KoreaUniversity, Korea

Session 4-2: Fragment-Based Drug Discovery and Ligand-Based Drug DesignTime: 11:10-12:00, November 4, 2011 (Friday) Place: Room No. 2, 1st Floor, SCEC

Session Chair Dr. Brian Dymock, Head, Chemistry, S*BIO Pte Ltd., Singapore

11:10-11:35 Title: Discovery of Low Molecular Weight Kinase Inhibitors for Important Pathways in Cancer andAutoimmune DiseaseDr. Brian W Dymock, Head, Chemistry, S*BIO Pte Ltd., Singapore

11:35-12:00 Title: Introducing Affinity LC/MS as a Tool for Fragment ScreeningDr. Sten Ohlson, Professor, Division of Biochemistry/Biotechnology, School of Natural Sciences, Linnaeus University, Sweden

Session 4-3: Targeting Protein Folding and Protein-Protein InteractionTime: 10:30-12:10, November 4, 2011 (Friday) Place: Room No. 6, 1st Floor, SCEC

Session Chair Dr. Borbala Gesser, Associate Professor, Department of Dermatology, Aarhus University Hospital,Denmark

10:30-10:55 Title: Structure-based Design of CXCL12 Inhibitors that Prevent CXCR4 ActivationDr. Yu Chen, Assistant Professor, Department of Molecular Medicine, College of Medicine, Universityof South Florida, USA

10:55-11:20 Title: Dimethylfumarate Inhibits MIF Induced Proliferation of Keratinocytes by Inhibiting MSK1 and RSK1 Activation and by Inducing Nuclear p-c-Jun (S63) and p-p53 (S15) Expression. PossibleRole for Its Anti-Psoriatic EffectDr. Borbala Gesser, Associate Professor, Department of Dermatology, Aarhus University Hospital,Denmark

11:20-11:45 Title: IL-18 and IL-18BP in Autoimmune Diseases and Poxvirus InfectionDr. Junpeng Deng, Assistant Professor, Department of Biochemistry and Molecular Biology, Oklahoma State University, USA

11:45-12:10 Title: Targeting TNFa with Small Molecule Inhibitors of the TNF-TNFR InteractionDr. Jessica M. Davis, Assistant Professor, Department of Chemistry & Biochemistry, Fairfield University, USA

020


Session 4-4: Targeting the Endocannabinoid SystemTime: 08:30-10:35, November 4, 2011 (Friday) Place: Room No. 7, 1st Floor, SCEC

Session Chair Dr. David F. Woodward, Senior Director, Department of Biological Sciences, Allergan Inc., USA

08:30-08:55 Title: Development of Peripherally Restricted CB1 Antagonists for Treatment of Obesity and DiabetesDr. Thomas Högberg, Associate Professor and Director, Chemical Research, LEO Pharma A/S, Denmark

08:55-09:20 Title: Identification of Endocannabinoids and Their Cyclo-oxygenase-2 (COX-2) Derived BiosyntheticProducts for Use in GlaucomaDr. David F. Woodward, Senior Director, Department of Biological Sciences, Allergan Inc., USA

09:20-09:45 Title: Cellular Dielectric Spectroscopy: A Cost Effective and Eco-friendly Method for Drug DiscoveryDr. Jenny Wang, Senior Scientist, Fatty Acid Amide Program, Allergan Inc., USA

09:45-10:10 Title: Brain Cannabinoid CB2 Receptor Modulates Cocaine’s Actions in MiceDr. Zheng-Xiong Xi, Associate Scientist, Neuropsychopharmacology Section, Chemical Biology Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutesof Health, USA

10:10-10:35 Title: Endocannabinoid Regulation of Skeletal Muscle Metabolism - Is it still a Target for Obesity and Diabetes?Dr. Andrew J. McAinch, Senior Lecturer Nutrition, School of Biomedical and Health Sciences, Victoria University, Australia

Session 4-5: Emerging Enzyme Target InhibitorsTime: 10:55-12:10, November 4, 2011 (Friday) Place: Room No. 7, 1st Floor, SCEC

Session Chair Dr. Nariyoshi Shinomiya, Professor, Department of Integrative Physiology and Bio-Nano Medicine,National Defense Medical College, Japan

10:55-11:20 Title: Structure-Based Drug Design Leading to Potent and Selective Irreversible HCV Protease InhibitorsDr. Deqiang Niu, Associate Director, Avila Therapeutics, Inc., USA

11:20-11:45 Title: Development of Small Molecule Inhibitors for Met, a Receptor Tyrosine KinaseDr. Nariyoshi Shinomiya, Professor, Department of Integrative Physiology and Bio-Nano Medicine,National Defense Medical College, Japan

11:45-12:10 Title: Screening from Nature and Molecular Design of Signal Transduction Inhibitors Active on Inflammation and CancerDr. Kazuo Umezawa, Professor of Biochemistry, Chairman, Center for Chemical Biology, Keio University, Japan

Session 4-6: Quantum Methods for Structure-Based Drug DesignTime: 08:30-10:10, November 4, 2011 (Friday) Place: Room No. 8, 1st Floor, SCEC

Session Chair Dr. Herbert Treutlein, Co-Founder and CEO, Qubist Molecular Design Pty. Ltd., Australia

08:30-08:55 Title: Quantum Mechanical Methods for Fragment-based Design of Malaria DrugsDr. Herbert R. Treutlein, Co-Founder and CEO, Qubist Molecular Design Pty. Ltd., Australia

021


08:55-09:20 Title: Design and Application of a Novel Scoring Function Based on Semiempirical Quantum Mechanical PM6-DH2X Method Accuratelly Describing Dispersion Energy as well as Hydrogen and Halogen BondingDr. Pavel Hobza, Professor of Physical Chemistry, Palacký University, Czech Republic

09:20-09:45 Title: It Moves! Novel Algorithms for Fast and Reliable Molecular Docking. Consideration of Entropic and Quantum EffectsDr. Agnieszka K. Bronowska, Principal Investigator, Heidelberg Institute for Theoretical Studies, Germany

09:45-10:10 Title: Ligand Conformational and Solvation Free Energy in Protein-Ligand Complex FormationDr. Jindrich Fanfrlik, Postdoctoral Fellowship, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Czech Republic

Session 4-7: Pharmacophore Methods in Drug DesignTime: 10:30-12:10, November 4, 2011 (Friday) Place: Room No. 8, 1st Floor, SCEC

Session Chair Dr. János T. Kodra, Head of Department, Protein & Peptide Chemistry 2, Novo Nordisk A/S, Denmark

10:30-11:55 Title: The Use of Pharmacophore Guided Parallel Synthesis for the Discovery of Selective GlucagonAntagonistsDr. János T. Kodra, Head of Department, Protein & Peptide Chemistry 2, Novo Nordisk A/S, Denmark

10:55-11:20 Title: Quasi-live Self-Assembled Supramolecular Drugs for Treatment of Actual DiseasesDr. Sonya Sophya Farber, Chief Communications Officer, Noigel, Inc., USA

11:20-11:45 Title: GRID-based Pharmacophore Elucidation and Virtual ScreeningDr. Simon Cross, Senior Scientist and Product Manager, Molecular Discovery Limited, UK

11:45-12:10 Title: Library Design and in Silico Screening Strategy to Identify Drug Candidates for Orphan 7TMReceptorsDr. Thomas Michael Frimurer, Associated Professor, Faculty of Health Sciences, Center for BasicMetabolic Research, University of Copenhagen, Denmark

Session 4-8: QSAR and 4D QSAR Based Drug DesignTime: 10:30-11:20, November 4, 2011 (Friday) Place: Room No. 9, 1st Floor, SCEC

Session Chair Dr. Rumin Zhang, Biophysics Team Lead, In Vitro Pharmacology, Merck Research Laboratories, USA

10:30-11:55 Title: Kinetically Perceptive and Mechanism of Action Informed SAR in Drug DiscoveryDr. Rumin Zhang, Biophysics Team Lead, In Vitro Pharmacology, Merck Research Laboratories, USA

10:55-11:20 Title: Involvement of NF-*B in the Suppression of Cyclooxygenase-2 and Apoptosis of A549 CellsInduced by BrucineDr. Guangwen Shu, Associate Professor, College of Pharmacy, South-Central University, China

022


Chapter 5: Leading Drug Discovery Technology

Session 5-1: Lab-On-a-Chip/MicrofluidicsTime: 13:30-14:20, November 4, 2011 (Friday) Place: Room No. 2, 1st Floor, SCEC

Session Chair Dr. Cathy Owen, CEO & President, Nanopoint, Inc., USA

13:30-13:55 Title: Examining the Capabilities of Microfluidics for Drug Screening ApplicationsMrs. Cathy Owen, CEO & President, Nanopoint, Inc., USA

13:55-14:20 Title: Ion Channel Drug Screening Platform: A Planar Patch-Clamp Chip Integrated with On-Demand Solution GenerationDr. De-Shien Jong, Associate Professor, National Taiwan University, Taiwan

Session 5-2: MS, LC-MS in Drug DiscoveryTime: 13:30-14:45, November 4, 2011 (Friday) Place: Room No. 3, 1st Floor, SCEC

Session Chair Dr. Wulff Niedner, Manager, LC Products, Thermo Fisher Scientific, Germany

13:30-13:55 Title: LC-MS/MS Assays for Peptides and Proteins in Drug Discovery and DevelopmentDr. Jaap Wieling, Vice President, Bioanalysis and Technology R&D, QPS, The Netherlands

13:55-14:20 Title: Towards Standard-free Quantitative and Qualitative Analysis in Liquid ChromatographyDr. Wulff Niedner, Manager, LC Products, Thermo Fisher Scientific, Germany

14:20-14:45 Title: Comprehensive Quantitative and Qualitative Liquid Chromatography–Radioisotope–Mass Spectrometry Analysis for Safety Testing of Tolbutamide Metabolites without Standard SamplesDr. Zenzaburo Tozuka, Research Fellow and Scientific Adviser, ADME & Tox. Research Institute,Sekisui Medical Co., LTD., Japan

Session 5-3: NMR and In Vivo MR Techniques in Drug DiscoveryTime: 15:30-17:10, November 4, 2011 (Friday) Place: Room No. 2, 1st Floor, SCEC

Session Chair Dr. Jun Hu, Senior NMR Spectroscopist, AstraZeneca, USA

15:30-15:55 Title: Modern NMR Applications in Drug DiscoveryDr. Jun Hu, Senior NMR Spectroscopist, AstraZeneca, USA

15:55-16:20 Title: Observed = Quantified: Validations and Applications of Universal NMR Quantitation MethodsDr. Huaping Mo, Associate Director, Shanghai Institute of Organic Chemistry, China

16:20-16:45 Title: Automated NMR in Fragment Based Lead DiscoveryDr. Ke Ruan, Associate Professor, School of Life Science, University of Science and Technology of China, China

16:45-17:10 Title: In vivo MR Measurement of Refracative Index and T2 Relaxation Time with Clinical Applicationto Discriminate Various Brain Lesions NoninvasivelyDr. Tapan K. Biswas, Radiologist & Rsearcher, Biswas X Ray & Scan Centre, India

023


Session 5-4: X-Ray and Crystallography in Drug DiscoveryTime: 13:30-17:10, November 4, 2011 (Friday) Place: Room No. 4, 1st Floor, SCEC

Session Chair Dr. Richard Pauptit, Associate Director and Principal Scientist, Global Structural Chemistry AstraZeneca, UK

Co-Chair Dr. Bob B. He, Director of Innovation and Business, Development-XRD2, Bruker AXS Inc., USA

13:30-13:55 Title: Structural Biology in the Disocvery of Diabetes Protein TherapeuticsDr. Gerd Schluckebier, Team Leader, Structural Biology, Novo Nordisk A/S, Denmark

13:55-14:20 Title: Crystallography and BiopharmaceuticalsDr. Richard A. Pauptit, Senior Principal Scientist; Discovery Enabling Capabilities and Sciences, AstraZeneca, UK

14:20-14:45 Title: Structure-based Design of New Generation AnticoagulantsDr. Herbert Nar, Director Structural Research, Lead Identification and Optimization Support, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany

14:45-15:10 Title: Providing Electron Density From High Resolution X-Ray Data as Complementary Informationto Drug DevelopmentDr. Peter Luger, Professor, Institute for Chemistry Crystallography, Free University Berlin, Germany


15:30-15:55 Title: Two-Dimensional X-Ray Diffraction for PharmaceuticalDr. Bob B. He, Director of Innovation and Business, Development-XRD2, Bruker AXS Inc., USA

15:55-16:20 Title: Expecting the Unexpected: Ligand-Induced Conformational Changes of Drug Targets Revealedby Protein CrystallographyDr. Xin Chen, Principal Research Investigator, Sanofi-Aventis, USA

16:20-16:45 Title: Better Data with PILATUS detectorsDr. Clemens Schulze-Briese, CSO, Dectris Ltd., Switzerland

16:45-17:10 Title: Inclusion Complexes and Co-crystals of Calixarenes with Drug Molecules - A Possible New Forms of PharmaceuticalsDr. Kinga Suwinska, Associate Professor, Institute of Physical Chemistry, Polish Academy of Sciences, Poland

Session 5-5: Biomarker Methods in Drug Discovery and DevelopmentTime: 13:30-14:20, November 4, 2011 (Friday) Place: Room No. 5, 1st Floor, SCEC

Session Chair Dr. Khusru Asadullah, Head of Global Biomarker, Bayer HealthCare Pharmaceuticals, Bayer PharmaAG, Germany

13:30-13:55 Title: Biobanking as an Integrated Part of Biomarker ResearchDr. Khusru Asadullah, Head of Global Biomarker, Bayer HealthCare Pharmaceuticals, Bayer PharmaAG, Germany

13:55-14:20 Title: Human Primary Tumor Model Platform for Oncology Drug DiscoveryDr. Danyi Wen, Vice President, Biology, External Collaboration & Business Development, IACUCChairman, Shanghai ChemPartner, Co. Inc., China

024


Session 5-6: Molecular Imaging TechnologyTime: 15:30-16:45, November 4, 2011 (Friday) Place: Room No. 3, 1st Floor, SCEC

Session Chair Dr. Zhong Zhong, Senior Director of Discovery Technology, GlaxoSmithKline RD, China

15:30-15:55 Keynote SpeechTitle: From the Cell to the Animal to the Human - Translational NIR Biomarker ImagingDr. Jacob G. Tesdorpf, Director Imaging Platforms, PerkinElmer, USA

15:55-16:20 Title: Cell Imaging Assays in Drug DiscoveryDr. Zhong Zhong, Senior Director of Discovery Technology, GlaxoSmithKline RD, China

16:20-16:45 Title: Molecular Imaging in Drug Delivery and Drug DiscoveryDr. Rao Papineni, Distinguished Scientist and Senior Principal Investigator, Research and Development,Carestream Molecular Imaging, USA

Session 5-7: Phage Display in Drug DiscoveryTime: 13:30-14:45, November 4, 2011 (Friday) Place: Room No. 6, 1st Floor, SCEC

Session Chair Dr. Chung-Ming Hsieh, Associate Director, Antibody Generation Group, Abbott Bioresearch Center,USA

13:30-13:55 Title: Antibody Discovery and Engineering by mRNA and Yeast Displays, A Powerful CombinationDr. Chung-Ming Hsieh, Associate Director, Antibody Generation Group, Abbott Bioresearch Center,USA

13:55-14:20 Title: Peptide Phage Display as a Tool for Identification of Vectors for Targeted Diagnostic ImagingDr. Astrid Hilde Myrset, CEO of Omegatri AS, Norway

14:20-14:45 Title: Molecular Signature-recognizing Peptides: Discovery and Uses for Imaging and Drug DeliveryDr. Byung-Heon Lee, Associate Professor, Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Korea

Session 5-8: Bioinformatics, Computational Biology and ChemoinformaticsTime: 13:30-14:20, November 4, 2011 (Friday) Place: Room No. 7, 1st Floor, SCEC

Session Chair Dr. Hugo Geerts, Chief Scientific Officer, In Silico Biosciences; Adj Associate Professor, School of Medicine, University of Pennsylvania, USA

13:30-13:55 Title: Integration not Isolation: The Role of Systems Pharmacology in Drug Discovery and DevelopmentDr. Balaji Agoram, Director, Clinical Pharmacology/DMPK, MedImmune, UK

13:55-14:20 Title: Re-engineering CNS Drug R & D Using Computer-Based Mechanistic Modeling and SimulationDr. Hugo Geerts, Chief Scientific Officer, In Silico Biosciences; Adj Associate Professor, School of Medicine, University of Pennsylvania, USA

025


Chapter 6: Frontier in Small Molecule Drug Discovery

Session 6-1: Frontier in Small Molecule Drug DiscoveryTime: 13:30-16:45, November 4, 2011 (Friday) Place: Room No. 8, 1st Floor, SCEC

Session Chair Dr. Jin Li, Director of Global Compound Sciences, AstraZeneca PLC, UKCo-Chair Dr. Mark A Myers, Program Coordinator and Lecturer in Biomedical Science, School of Health

Sciences, University of Ballarat, Australia

13:30-13:55 Title: Novel Approaches to Discovering Ligands for GPCRsDr. Jin Li, Director, Global Compound Sciences, DECS Lead Generation, AstraZeneca R & D, UK

13:55-14:20 Title: Identification of Novel Peptide Agonists for a G Protein Coupled Receptor from a Random Peptide LibraryDr. Shigeki Takeda, Professor, Department of Chemical Biology, Gunma University Graduate Schoolof Engineering, Japan

14:20-14:45 Title: Anticancer Bioactive Peptide Potentiates Cisplatin Chemotherapy Efficacy and Improves theQuality of Life in Xenografted Nude Mice Bearing Human Gastric CancerDr. Xiulan Su, Director, Clinical Research Center of Affiliated Hospital, Inner Mongolia Medical College, China

14:45-15:10 Title: In Silico Search and Syntheis of Flavin Analogs as Protein Kinase Inhibitors and Antitumor ActivitiesDr. Tomohisa Nagamatsu, Associate Professor & Head, Department of Molecular PharmaceuticalChemistry, Okayama University, Japan


15:30-15:55 Title: Zinc Chelation and Insulin Hexamer Dispersal by PeptidesDr. Mark A Myers, Program Coordinator and Lecturer in Biomedical Science, School of Health Sciences, University of Ballarat, Australia

15:55-16:20 Title: Selective Inhibitors for the Integrins *v*3 and *5*1 and Their Use in MedicineDr. Horst Kessler, Carl von Linde Senior Fellow, Department of Chemistry, Institute for AdvancedStudy, Technical University of Munich, Germany

16:20-16:45 Title: Identification of New GATA4-small Molecule Inhibitors by Structure-based Virtual ScreeningDr. Georges Nemer, Associate Professor, Department of Biochemistry and Molecular Genetics, American University of Beirut, Lebanon

Chapter 7: Breaking Biotherapy Discovery and Development

Session 7-1: Protein TherapeuticsTime: 15:30-17:10, November 4, 2011 (Friday) Place: Room No. 5, 1st Floor, SCEC

Session Chair Dr. Alexey M. Kopylov, Professor, Chemistry Department and Institute of Physico Chemical Biology, Moscow State University; Apto-Pharm Ltd, Russia

Co-Chair Dr. Girish J. Kotwal, Professor of Biochemistry and Microbiology, University of Medicine and Health Sciences, St. Kitts

15:30-15:55 Title: RNA Aptamer: The Next Generation of Cancer Stem Cell-targeted Molecular ImagingDr. Wei Duan, Professor, School of Medicine, Deakin University, Australia

15:55-16:20 Title: Anticoagulant Activity of Thrombin-binding DNA AptamersDr. Alexey M. Kopylov, Professor, Chemistry Department and Institute of Physico Chemical Biology,Moscow State University; Apto-Pharm Ltd, Russia

026


16:20-16:45 Title: Vaccinia Virus Compliment Control Protein, a Protein Therapeutic for Controlling Inflammationin Alzheimer’s Disease, Arthritis, Atherosclerosis, Cns Injury and Number of Other DiseasesDr. Girish J. Kotwal, Professor of Biochemistry and Microbiology, University of Medicine and Health Sciences, St. Kitts

16:45-17:10 Title: Rational Improvement of Aptamers to Gain Therapeutics Value. Problems and SolutionsDr. Golovin Andrey, Molecular Biologist, Lomonosov Moscow State University, Russia

Session 7-2: Vaccine Innovation & BiotherapyTime: 15:05-17:10, November 4, 2011 (Friday) Place: Room No. 6, 1st Floor, SCEC

Session Chair Dr. Bernd Eisele, CEO, Vakzine Projekt Management GmbH, GermanyCo-Chair Dr. Matthew Sleeman, Director of Biology, Respiratory, Inflammation and Autoimmunity Group

(RIA), UK

15:05-15:30 Title: Tuberculosis: Improved Immunogenicity after Vaccination with the Live Recombinant VaccineVPM1002 in Phase I Clinical TrialsDr. Bernd Eisele, CEO, Vakzine Projekt Management GmbH, Germany

15:30-15:55 Title: Novel IgE/cytokine Peptide-based Virus-like Particle Vaccines for Treatment of Allergic and Autoimmune DiseasesDr. Zhikang Peng, Professor, Department of Pediatrics and Child Health, Department of Immunology,University of Manitoba, Canada

15:55-16:20 Title: Mavrilimumab, A Novel Anti GMCSFR Alpha Antibody Targeting Macrophages in RheumatoidArthritisDr. Matthew Sleeman, Director of Biology, Respiratory, Inflammation and Autoimmunity Group (RIA), UK

16:20-16:45 Title: From Discovery in Academic Setting to Administration in Humans – Developing TherapeuticAntibodies Against Rare DiseasesDr. Dimiter S Dimitrov, Senior Investigator, NCI, NIH, USA

16:45-17:10 Title: Quadrivalent HPV 6/11/16/18 Vaccine Efficacy against Cervical and External Genital Diseasein Subjects with Prior Vaccine HPV Type InfectionDr. Sven-Eric Olsson, Associate Professor, Karolinska Institute at Danderyd Hospital, Sweden

Session 7-3: ImmunotoxinTime: 15:30-17:10, November 4, 2011 (Friday) Place: Room No. 7, 1st Floor, SCEC

Session Chair Dr. Gabriel Lasala, President, TCA Cellular Therapy, USA

15:30-15:55 Title: Combination Stem Cell Therapy for Severe Limb IschemiaDr. Gabriel Lasala, President, TCA Cellular Therapy, USA

15:55-16:20 Title: Reversal of Type 1 Diabetes through the Immune Modulation of Cord Blood-Derived MultipotentStem Cells in HumansDr. Yong Zhao, Assistant Professor, Section of Endocrinology, Diabetes and Metabolism, Departmentof Medicine, University of Illinois at Chicago, USA

16:20-16:45 Title: Antibody-Based Fusion Proteins to Target Death Receptors in CancerDr. Edwin Bremer, Assistant Professor, Department of Surgical Research Laboratory, University Medical Center Groningen, The Netherlands

16:45-17:10 Title: Therapeutic Attenuation of Silica-Induced Pulmonary Fibrosis by Immunotoxin Chimeric Molecule il-13peDr. Patrícia Martins, Senior Researcher, Laboratory of Inflammation, Oswaldo Cruz Foundation, Brazil

027


Chapter 8: Genome-Based Drug Discovery and Development

Session 8-1: Genome-Based Drug Discovery and DevelopmentTime: 08:30-11:45, November 5, 2011 (Saturday) Place: Room No. 1, 1st Floor, SCEC

Session Chair Dr. Paolo Mascagni, Director of Preclinical R & D, Italfarmaco Spa, ItalyCo-Chair Dr. Carsten Rosenow, Associate Director, Global Market, Development of Genotyping, Illumina,

Inc., USA

08:30-08:55 Title: Dried Blood Spot Sampling in Drug Development Studies for Pharmacokinetics, Pharmacogenomics and Safety AssessmentsDr. Jaap Wieling, Vice President, Bioanalysis and Technology R & D, QPS, The Netherlands

08:55-09:20 Title: Understanding Health and Disease Through Genomic Research: New Drug Target DiscoveryUtilizing Array and Sequencing TechnologyDr. Carsten Rosenow, Associate Director, Global Market, Development of Genotyping, Illumina, Inc., USA

09:20-09:45 Title: A New Toolbox in Functional Proteomics •Getting a Focused Picture of Drug Action•Dr. Friedrich Kroll, Head, Medicinal Chemistry, Caprotec Bioanalytics GmbH, Germany

09:45-10:10 Title: Gene Therapy for Glaucoma: Insights into the Pharmacology of the FutureDr. Paul L. Kaufman, Professor & Chair, Department of Ophthalmology & Visual Sciences, Schoolof Medicine & Public Health, University of Wisconsin-Madison, USA


10:30-10:55 Title: The Pleotropic Activity of HDAC Inhibitors from Auto-immunity to Cancer to NeurodegenerativeDisordersDr. Paolo Mascagni, Director of Preclinical R & D, Italfarmaco Spa, Italy

10:55-11:20 Title: Application of Metabolomics in Preclinical Toxicology StudiesDr. Yutai Li, Research Fellow, Merck, USA

11:20-11:45 Title: Targeted Alpha Therapy for CancerDr. Graeme Melville, Senior Researcher, Centre for Radiation Oncology, St George Hospital, Australia

Chapter 9: Traditional Chinese Medicine vs Natural Product based Drug Discovery

Session 9-1: Traditional Chinese Medicine vs Natural Product based Drug DiscoveryTime: 08:30-11:20, November 5, 2011 (Saturday) Place: Room No. 2, 1st Floor, SCEC

Session Chair Dr. Cory J. Xian, Professor of Bone Research & NHMRC Senior Research Fellow, Bone Growth and Repair Research Group, Sansom Institute, School of Pharmacy and Medical Sciences, Universityof South Australia, Australia

08:30-08:55 Title: Antioxidant and Oxidative Activity, Composition and Functionalities of Whole Coffee Fruits and Their ExtractDr. Boris Nemzer, Director of Research and Development, FutureCeuticals, Inc., USA

08:55-09:20 Title: Nutraceuticals for Preventing Bone Loss Following Cancer ChemotherapyDr. Cory J. Xian, Professor of Bone Research & NHMRC Senior Research Fellow, Bone Growth and Repair Research Group, Sansom Institute, School of Pharmacy and Medical Sciences, Universityof South Australia, Australia

028


09:20-09:45 Title: Natural Compounds that Stimulate Bone and Periodontal Tissue Formation - Harmine, Acerogenins and HonokiolsDr. Je Tae Woo, Professor, Biological Chemistry Department, College of Bioscience and Biotechnology,Chubu University, Japan

09:45-10:10 Title: Study on Effects and Mechanisms of Compatibility of Periplocin and Panax Notoginseng SaponinDr. Han Zhang, Assistant Research Fellow, Tian Jin University of Traditional Medicine, China


10:30-10:55 Title: The Anti-Tumor Effects of Flavonoids from the Ethnic Medicine Docycia Delavayi (Franch) Schneid and its Possible MechanismDr. Xukun Deng, Associate Professor, College of Pharmacy, South-Central University, China

10:55-11:20 Title: Potential Medicinal Plants for Diabetes and ObesityDr. Vikas Kumar, Reader in Pharmacology, Department of Pharmaceutics, Institute of Technology,Banaras Hindu University, India

Chapter 10: Pipeline Update on IND against Major Diseases

Session 10-1: Cardiovascular DiseasesTime: 08:30-09:45, November 5, 2011 (Saturday) Place: Room No. 3, 1st Floor, SCEC

Session Chair Dr. Kewei Wang, Professor and Chair, Peking University School of Pharmaceutical Sciences; Professor of Neurobiology, Peking University School of Medicine, China

08:30-08:55 Title: Domestic and Miniature Swine as Models in Toxicology and Drug DiscoveryDr. Michael Swindle, Professor, Department of Comparative Medicine, Medical University of SouthCarolina, USA

08:55-09:20 Title: Preclinical Cardiovascular Safety ModelsDr. Michael Markert, Principal Scientist, Department of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany

09:20-09:45 Title: Synthesis, Screening and Biological Activity of Novel Kv7/Kcnq/M-Channel Modulators for Neuropsychiatric DisordersDr. Kewei Wang, Professor and Chair, Peking University School of Pharmaceutical Sciences; Professor of Neurobiology, Peking University School of Medicine, China

Session 10-2: Neurodegenerative DiseasesTime: 08:30-11:45, November 5, 2011 (Saturday) Place: Room No. 4, 1st Floor, SCEC

Session Chair Dr. Ratan Bhat, Director and Head of Portfolio Enhancement, AstraZeneca Research and Development,Innovative Medicines CNS & Pain, Sweden

Co-Chair Dr. Yves P. Auberson, Executive Director, Novartis Institutes for BioMedical Research, Switzerland

08:30-08:55 Title: Bace1 Inhibitors for the Treatment of Alzheimer’s DiseaseDr. Johanna Fälting, iMed Project Director, AstraZeneca Research and Development, Sweden

08:55-09:20 Title: Targeting Tau in Alzheimer´s DiseaseDr. Ratan Bhat, Director and Head of Portfolio Enhancement, AstraZeneca Research and Development,Innovative Medicines CNS & Pain, Sweden

029


09:20-09:45 Title: Ryanodine Receptor III as a Target of Drug Design for NeurodegenerationDr. Kenneth T. Wann, Professor, Welsh School of Pharmacy, Cardiff University, UK

09:45-10:10 Title: BGG492, A Competitive AMPA/Kainate Antagonist in Clinical Development for the Treatmentof EpilepsyDr. Yves P. Auberson, Executive Director, Novartis Institutes for BioMedical Research, Switzerland


10:30-10:55 Title: Functionalized Magnetonanoparticles in Visualization of Function and Disease on MRIDr. Massoud Akhtari, Professor, University of California, Los Angeles Health System, USA

10:55-11:20 Title: Pharmacogenomic Approaches to NeuroprotectionDr. Z. Carl Lin, Assistant Professor, McLean Hospital, Harvard Medical School, USA

11:20-11:45 Title: New Paradigm Drug Design, Catalytic Drug on Amyloidogenic DiseasesDr. Keunhong Jeong, Assistant Professor, Department of Chemistry, Korea Military Academy, Korea

Session 10-3: Mental Disease Drug DiscoveryTime: 10:05-12:10, November 5, 2011 (Saturday) Place: Room No. 3, 1st Floor, SCEC

Session Chair Dr. Roumen Milev, Professor of Psychiatry and Psychology; Head, Queen’s University, Canada

10:05-10:30 Title: Deep Lung Delivery of Inhaled Pure Nicotine for Smoking CessationDr. Igor Gonda, CEO and President, Aradigm Corporation, USA

10:30-10:55 Title: Sleeping Problems in Neuropsychiatric DisordersDr. Taina Nieminen-von Wendt, CEO, NeuroMental, Finland

10:55-11:20 Title: Is There a Role of Polysomnogram (PSG) in the Evaluation of Drugs for Mood Disorders?Dr. Roumen Milev, Professor of Psychiatry and Psychology; Head, Queen’s University, Canada

11:20-11:45 Title: Neu-P11: A Novel Melatonin-Serotonin Agonist for the Treatment of InsomniaDr. Moshe Laudon, Director, Drug Discovery, Neurim Pharmaceuticals Ltd., Israel

11:45-12:10 Title: Stress Biomarkers' Associations to Pain in the Neck, Shoulder and Back in Healthy Media Workers: 12-Month Prospective Follow-upDr. Elisabet Schell, Lecturer and Superviser, Department of Molecular Medicine and Surgery, Karolinska Institutet, Sweden

Session 10-4: Diabetes & Other Metabolic Diseases

Session 10-4-1: Diabetes Drug Discovery and TherapyTime: 08:30-12:10, November 5, 2011 (Saturday) Place: Room No. 5, 1st Floor, SCEC

Session Chair Dr. Lily Stojanovska, Associate Head, School of Biomedical and Health Sciences, Faculty of Health,Engineering and Science, Victoria University, Australia

Co-Chair Dr. Chris Triggle, Professor, Departments of Medical Education and Pharmacology, Weill CornellMedical College in Qatar, Qatar

08:30-08:55 Title: Gestational Diabetes AKA Type 2 DiabetesDr. Lisa E Moore, Chief of the division of Maternal Fetal Medicine, University of New Mexico, USA

08:55-09:20 Title: The Role of Insulin Sensitizers in the Management of Insulin Resistance and Type 2 DiabetesDr. Lily Stojanovska, Associate Head, School of Biomedical and Health Sciences, Faculty of Health,Engineering and Science, Victoria University, Australia

030


09:20-09:45 Title: Two Important DiscoveriesDr. Luc F. Van Gaal, Professor of Medicine, Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, Belgium

09:45-10:10 Title: A Novel AMPK Activator Based from Natural ProductsDr. Wei Wu, General Manager, Hainan Deze Drug Research Co., Ltd, China


10:30-10:55 Title: Protecting the EndotheliumDr. Chris R Triggle, Professor, Departments of Medical Education and Pharmacology, Weill CornellMedical College in Qatar, Qatar

10:55-11:20 Title: Ginsenoside Rb1: A Novel Antiobesity and Antihyperglycemic CompoundDr. Min Liu, Associate Professor, College of Medicine, University of Cincinnati, USA

11:20-11:45 Title: Bile Acid Metabolism for the Control of Metabolic SyndromeDr. Mitsuhiro Watanabe, Associate Professor, Department of Internal Medicine, Keio University, Japan

11:45-12:10 Title: Pharmacogenomics of PioglitazoneDr. Sandeep K Mathur, Professor, Department of Endocrinology, S.M.S. Medical College, India

Session 10-4: Diabetes & Other Metabolic Diseases

Session 10-4-2: Diabetes Related Metabolic Complications and Other Metabolic DiseasesTime: 08:30-11:20, November 5, 2011 (Saturday) Place: Room No. 6, 1st Floor, SCEC

Session Chair Dr. Sudarshan Ramachandran, Consultant Biochemist, Department of Biochemistry, Good HopeHospital NHS Trust, UK

08:30-08:55 Title: Pharmacotherapy for Weight Management – A Past, Present, but still a Future?Dr. Andrew Hartland, President, Pathology Section of the Royal Society of Medicine; UK Senior Lecturer, Division of Medicine, University of Birmingham, UK

08:55-09:20 Title: Interesting Observations in HDL-cholesterol and Creatinine Levels Following Fibrate and Glitazone Use in a Real World Metabolic ClinicDr. Sudarshan Ramachandran, Consultant Biochemist, Department of Biochemistry, Good HopeHospital NHS Trust, UK

09:20-09:45 Title: The Clock Genes. A New Approach for the Treatment of Obesity and Type II DiabetesDr. Daniela Jakubowicz, Professor of Medicine & Endocrinology, Virginia Commonwealth University,USA; Professor of Medicine VCU, Wolfson Hospital University of Tel Aviv, Israel

09:45-10:10 Title: The Progress of Pharmacotherapy on Diabetic RetinopathyDr. Xinyuan Zhang, Professor, Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, China


10:30-10:55 Title: Hypoglycemia: A Possible Link between Insulin Resistance and the Metabolic Syndrome DyslipidemiaDr. Myriam CristinaYafar Ensling, Assistant professor, Center for Health Care Quality, Universityof Missouri-Columbia, USA

10:55-11:20 Title: Targeting SREBP-1 Regulated Lipid Metabolism to Treat CancerDr. Deliang Guo, Assistant Professor, Department of Radiation Oncology, James Comprehensive Cancer Center, The Ohio State University Medical Center, USA

031


Session 10-5: Severe Respiratory and Inflammation Diseases

Session 10-5-1: Drug Discovery Targeting Asthma and Chronic Obstructive Pulmonary Disease (COPD)Time: 13:30-15:10, November 5, 2011 (Saturday) Place: Room No. 1, 1st Floor, SCEC

Session Chair Dr. Andrzej Mariusz Fal, Professor & Chair, Department of Public Health, Wroclaw Medical University, Poland

Co-Chair Dr. Amr El-Shazly, Professor of Rhinology, Liege University Hospital, Belgium

13:30-13:55 Title: How Much Different is Asthma and COPD – Nearest Perspectives for New TherapiesDr. Andrzej Mariusz Fal, Professor & Chair, Department of Public Health, Wroclaw Medical University, Poland

13:55-14:20 Title: CX3CR1 Receptor is a Novel Target for Therapeutic Modalities in Allergic RhinitisDr. Amr El-Shazly, Professor of Rhinology, Liege University Hospital, Belgium

14:20-14:45 Title: Magic Role of Macrolides in COPD and Asthma. True or Myth?Dr. Ehsan Sabry, Professor, Asthma and Allergy Unit, Chest Department Kasr ALAini, Faculty ofMedicine Cairo University, Egypt

14:45-15:10 Title: Anti-Inflammatory & Anti-Asthmatic Natural Products from Medicinal PlantsDr. Sei-Ryang Oh, Principal Researcher; Director of Immune Modulator Research Center, Korea Research Institute of Bioscience & Biotechnology, Korea

Session 10-5: Severe Respiratory and Inflammation Diseases

Session 10-5-2: Anti-Inflammatory Drugs Targeting Cytokine, Chemokine, NFkb, Toll-Like Receptors TNF,and PhosphodiesterasesTime: 15:30-17:10, November 5, 2011 (Saturday) Place: Room No. 1, 1st Floor, SCEC

Session Chair Dr. Zhong Chen, Chief of Clinical Genomics Unit; Head and Neck Surgery Branch, National Instituteon Deafness and Other Communication Disorders, National Institutes of Health, USA

Co-Chair Dr. Tsutomu Akama, Research Leader, Medicinal Chemistry, Anacor Pharmaceuticals Inc., USA

15:30-15:55 Title: Identification and SAR of AN6414, A Potent and Orally Active Benzoxaborole PDE4 InhibitorDr. Tsutomu Akama, Research Leader, Medicinal Chemistry, Anacor Pharmaceuticals Inc, USA

15:55-16:20 Title: Targeting Caseine Kinase CK2 by Anti-CK2 Oligonucleotides via Sub-50nm Nanocapsules to Modulate NF-*B, TP53, And the Malignant Phenotype of Head and Neck CancerDr. Zhong Chen, Chief of Clinical Genomics Unit; Head and Neck Surgery Branch, National Instituteon Deafness and Other Communication Disorders, National Institutes of Health, USA

16:20-16:45 Title: Searching a Substrate for Denitrase, an Activity that Reduces Nitrotyrosine Immunoreactivityin ProteinsDr. Yasuyuki Irie, Associate Professor, Department of Pharmacology, Iwate Medical University, Japan

16:45-17:10 Title: Expression Change of Nnicotinic Receptor by the Cell Maturity in the APC Cell LineDr. Yukiko Kondo, Assistant Professor, Department of Pharmacology, Iwate Medical University, Japan

032


Session 10-6: Autoimmune and Other Severe Immune DiseasesTime: 13:30-15:10, November 5, 2011 (Saturday) Place: Room No. 2, 1st Floor, SCEC

Session Chair Dr. Ole Haagen Nielsen, Professor, Faculty of Health Sciences, University of Copenhagen; Chief Physician, Department of Gastroenterology, Medical Section, Denmark

13:30-13:55 Title: Biological Agents in Inflammatory bowel Disease(IBD): Current Concepts and Future ChallengesDr. Ole Haagen Nielsen, Professor, Faculty of Health Sciences, University of Copenhagen; Chief Physician, Department of Gastroenterology, Medical Section, Denmark

13:55-14:20 Title: PPARgamma agonist as a Potential Therapeutic Agent for Neuropathic PainDr. Maiko Hasegawa-Moriyama, Assistant Professor, Kagoshima University, Japan

14:20-14:45 Title: Novel Drug Applications in Immunologically-Related Fatigue SyndromesDr. Donald R. Staines, Associate Professor, Queensland Health, Australia

14:45-15:10 Title: Two Important DiscoveriesDr. Nooshin Bagherani, Dermatologist, Valiasr Hospital, Iran

Session 10-7: Antimicrobial Resistance Drug DiscoveryTime: 13:30-15:35, November 5, 2011 (Saturday) Place: Room No. 3, 1st Floor, SCEC

Session Chair Dr. Stephen Hawser, CEO, IHMA Europe Sàrl, Inc., Switzerland

13:30-13:55 Title: Non-Antibiotic Strategies: Game-Changing Antibacterial Drug Discovery?Dr. Marc Lemonnier, CEO, ANTABIO SAS, Prologue Biotech Technopark Labege, France

13:55-14:20 Title: Surveillance of Antibiotic ResistanceDr. Stephen Hawser, CEO, IHMA Europe Sàrl, Inc., Switzerland

14:20-14:45 Title: Drug Discovery to Combat Antibiotic ResistanceDr. Eugénie Bergogne-Bérézin, Professor of the Universities, Consultant in Microbiology, France

14:45-15:10 Title: Antiviral Therapy, If Detection of Polyomvirus in Cerebrospinal Fluid of Patients with Neurological Complications after Hematopoietic Stem Cell TransplantationDr. Britt Gustafsson, Associate Professor, Department of Pediatrics, Karolinska University Hospital-Huddinge, Sweden

15:10-15:35 Title: A New Drugs Delivery Systems Containing Natural Products for Control and Treatment of Candidiasis/Mucositis in Irradiated Head and Neck Patients; Plaque, Gingivitis and Dental CariesControlDr. Vagner Rodrigues Santos, Professor and Researcher, Faculty of Dentistry, University Federal

of Minas Gerais (UFMG), Brazil

Session 10-8: Drug Resistant TB and Malaria Drug DiscoveryTime: 15:30-16:45, November 5, 2011 (Saturday) Place: Room No. 2, 1st Floor, SCEC

Session Chair Dr. Alan Xiao, Director, Clinical Pharmacology & DMPK, AstraZeneca, USACo-Chair Dr. Jan-Cedric Hansen, Medico-Marketing European Strategist at StratAdviser Ltd, Medical

Coordinator at Hopital Asselin-Hedelin, France

15:30-15:55 Title: Model-based Optimal Early Development of AZD5847, A New Anti-TB DrugDr. Alan Xiao, Director, Clinical Pharmacology & DMPK, AstraZeneca, USA

033


15:55-16:20 Title: Literature Review on Current and Future Artemisinin-based Combination Therapy: Recent TrendsDr. Jan-Cedric Hansen, Medico-Marketing European Strategist at StratAdviser Ltd, Medical Coordinator at Hopital Asselin-Hedelin, France

16:20-16:45 Title: Novel Multistage Strategies Against MalariaDr. Miguel Prudêncio, Principal Investigator, Institute of Molecular Medicine, Portugal

Session 10-9: Novel Severe Virus Infectious DiseasesTime: 15:55-16:45, November 5, 2011 (Saturday) Place: Room No. 3, 1st Floor, SCEC

Session Chair Dr. Christopher W K Lam, Director of Pathology and Clinical Laboratory, University Hospital, Macau University of Science and Technology, Macau, China

15:55-16:20 Title: A Clinical Study of Rorric for the Prevention and Treatment of Influenza A InfectionDr. Shiu Hon Chui, Associate Professor, Macau University of Science and Technology, Macau, China

16:20-16:45 Title: New Strategies in Therapy and Drug Development of HIV InfectionDr. Nils von Hentig, Reader of Clinical Pharmacology and Senior House Officer, Johann WolfgangGoethe University Hospital, Germany

Session 10-10: Cancer Drug Discovery and DevelopmentTime: 13:30-16:20, November 5, 2011 (Saturday) Place: Room No. 4, 1st Floor, SCEC

Session Chair Dr. Dominic M. Desiderio, Professor, Department of Neurology, University of Tennessee Health Science Center, USA

13:30-13:55 Title: Apaziquone – A Novel Drug in Late Stage Development for Bladder CancerDr. Rajesh C. Shrotriya, Chairman and CEO, Spectrum Pharmaceuticals, Inc., USA

13:55-14:20 Title: The Nitroproteome of the Human PituitaryDr. Dominic M. Desiderio, Professor, Department of Neurology, University of Tennessee Health Science Center, USA

14:20-14:45 Title: Targeting of MDM2/XIAP Interaction for Cancer Drug DiscoveryDr. Muxiang Zhou, Professor, Emory University School of Medicine, USA

14:45-15:10 Title: Disruption of Hsp90 Function by Reactive Oxygen Species: A New Mechanism Explaining the Antitumoral Effects of Quinone CompoundsDr. Julien Verrax, Scientific Research Worker, Belgian National Fund for Scientific Research, Louvain Drug Research Institute, Catholic University of Louvain, Belgium


15:30-15:55 Title: Intraperitoneal Chemotherapy Using Nano-Drug for Peritoneal Metastasis by Gastric CancerDr. Joji Kitayama, Associate Professor, Department of Surgical Oncology, The University of Tokyo,Japan

15:55-16:20 Title: Carbon Ion Radiotherapy at Gunma UniversityDr. Tatsuya Ohno, Associate Professor, Gunma University Heavy Ion Medical Center, Gunma University, Japan

034


Chapter 11: New Drug Bioprocess and Production under GMP Standards

Session 11-1: Cell Therapy and Cell Culture ProcessingTime: 13:30-14:20, November 5, 2011 (Saturday) Place: Room No. 5, 1st Floor, SCEC

Session Chair Dr. Philippe R Henon, Professor, Cell Therapy at University of Haute Alsace, France; Director, the "Institut de Recherche en Hématologie et Transplantation", France

13:30-13:55 Title: GMP Production of CD34+ Cell Grafts for Post-Infarct Myocardial RegenerationDr. Philippe R Henon, Professor, Cell Therapy at University of Haute Alsace; Director, The "Research Institute of Hematology and Transplantation", France

13:55-14:20 Title: Improved Separation Technologies for the Production of BiopharmaceuticalsDr. Emile van de Sandt, Principal Scientist, DSM Biotechnology Center, The Netherlands

Session 11-2: Rapid Production and Formulation Process of BiopharmaceuticalsTime: 14:40-17:10, November 5, 2011 (Saturday) Place: Room No. 5, 1st Floor, SCEC

Session Chair Dr. Crystal Jaing, Group Leader, Applied Genomics, Lawrence Livermore National Laboratory, USA

14:40-15:05 Title: High Throughput Process Development Technologies and Their Application to Accelerate Early Stage Product DevelopmentDr. Christopher Yallop, COO and CSO, Batavia Bioservices, the Netherlands

15:05-15:30 Title: Pro and Cons of Dual Sourcing for BiopharmaceuticalsDr. Henri Kornmann, Director of Biotech Production, Merck Serono S.A., Switzerland

15:30-15:55 Title: A Microbial Detection Array Applied to Vaccine Safety and Quality Control of BiologicsDr. Crystal Jaing, Group Leader, Applied Genomics, Lawrence Livermore National Laboratory, USA

15:55-16:20 Title: Powder Products for Pulmonary or Intranasal DeliveryDr. Tom H. Jin, Scientist, Technique Operations/Manufacturing, Aeras Global TB Vaccine Foundation,USA

16:20-16:45 Title: New Concept for Modern Design of Modular Vaccine FacilitiesDr. Klaus Hermansen, Senior Specialist, Global Sales & Business Development, MSc Bio Engineering,NNE Pharmaplan, Denmark

16:45-17:10 Title: High Yield Recombinant Production of Therapeutic Peptide Hormones for GPCRsDr. Mohanraj Gopalswamy, Research Assistant, Institute of Physics/Biophysics, Martin-Luther-University of Halle-Wittenberg, Germany

Chapter 12: Me-too Drug Discovery and Biosimilars

Session 12-1: Me-Too Approaches to Improve Generic DrugsTime: 08:30-09:45, November 6, 2011 (Sunday) Place: Chrysanthemum Hall, 5th Floor, SCEC

Session Chair Dr. Daryl Fernandes, Chief Scientific Officer, Ludger Ltd., UK

08:30-08:55 Title: Effective Ways to Significantly Improve the Clinical Performance and Costs of Biopharmaceuticalsby Optimising Their GlycosylationDr. Daryl L. Fernandes, Founder and CEO, Ludger Ltd., UK

035


08:55-09:20 Title: Protein Enzymatic Conjugation: A Robust Technology for Biobetter PreparationDr. Giancarlo Tonon, General Manager, Bio-Ker s.r.l., Multimedica Group, Italy

09:20-09:45 Title: Controversies Surrounding Non-Proprietary Low Molecular Weight HeparinsDr. Frederick A. Ofosu, Professor Emeritus, Department of Pathology & Molecular Medicine, Faculty of Health Sciences, McMaster University, Canada

Session 12-2: Opportunities and Challenges for Biosimilars in the Global MarketTime: 10:30-12:10, November 6, 2011 (Sunday) Place: Chrysanthemum Hall, 5th Floor, SCEC

Session Chair Dr. Thomas Gelzleichter, Senior Scientist/ Group Leader ITGR, Genentech, Inc., USA

10:30-10:55 Title: Nonclinical Safety Studies in Support of Biosimilars Development: Industry PerspectiveDr. Thomas Gelzleichter, Senior Scientist/ Group Leader ITGR, Genentech, Inc., USA

10:55-11:20 Title: Opportunities and Challenges for Biosimilars: A Closer Look at the Global Insulin MarketDr. Kelly Close, President, Close Concerns, Inc., USA

11:20-11:45 Title: Biosimilars in the US: Not Gonna HappenDr. Claudia Wiatr, Senior Principal, Wolters Kluwer Pharma Solutions, UK

11:45-12:10 Title: US Biosimilars Patent Litigation Framework and StrategyDr. Brian V. Slater, Partner, Fitzpatrick, Cella, Harper & Scinto Intellectual Property Law, USA

Session 12-3: Legal, Patent, Regulatory and Pharmacovigilance on BiosimilarsTime: 08:30-10:10, November 6, 2011 (Sunday) Place: Peony Hall, 5th Floor, SCEC

Session Chair Dr. Kevin Murphy, Partner, Frommer Lawrence Haug LLP, USA

08:30-08:55 Title: Approval Pathways for Biosimilars in the U.S. and EUDr. Wendy Choi, Partner, Kilpatrick Townsend & Stockton LLP, USA

08:55-09:20 Title: Biosimilars under Obamacare: Biologics Price Competition and Innovation Act of 2009Dr. Kevin Murphy, Partner, Frommer Lawrence Haug LLP, USA

09:20-09:45 Title: The Biosimilars Framework in Europe: Prosecution and Litigation StrategiesDr. Christine Kanz, Lawyer, Reimann Osterrieth Köhler Haft, Germany

09:45-10:10 Title: Bioequivalence: What Does it Really MeansDr. Chong Chee Ping, Lecturer and Researcher, Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, University Sains Malaysia, Malaysia

Chapter 13: Key Issues in IND Filing and Regulatory Approval Process

Session 13-1: Key Issues in IND Filing and Regulatory Approval ProcessTime: 08:30-10:35, November 6, 2011 (Sunday) Place: Rose 1 Hall, 5th Floor, SCEC

Session Chair Dr. Beat Widler, Clinical Quality and Risk Management Expert, QAsperience, SwitzerlandCo-Chair Dr. Giovanni Dondi Dall’Orologio, Professor and Director, Division of Conservative Dentistry,

University of Bologna, Italy

08:30-08:55 Title: Quality Risk Management in Clinical Trials and PharmacovigilanceDr. Beat Widler, Clinical Quality and Risk Management Expert, QAsperience, Switzerland

08:55-09:20 Title: Orphan Drugs How They Change Both the R & D and Marketing Strategy of Pharma CompaniesDr. Jan-Cedric Hansen, Director, International Medical&n, StratAdviser Ltd., France

036


09:20-09:45 Title: The Use of Social Media as a Strategy for Patient Recruitment and Retention in Clinical TrialsDr. Diana L. Anderson, President and CEO, D. Anderson & Company, USA

09:45-10:10 Title: Understanding FDA’s Regulations and Policies in IND/NDA Review - A Key Successful Element for New Dug DevelopmentDr. Yuanchao (Derek) Zhang, Vice President, Regulatory Affairs and Clinical Pharmacology, Frontage Laboratories, Inc. USA

10:10-10:35 Title: CONSORT 2010 Statement: Updated Guidelines for Randomized TrialsDr. Giovanni Dondi Dall’Orologio, Professor and Director, Division of Conservative Dentistry, University of Bologna, Italy

Chapter 14: Drug Discovery Integrative Services, Deal-Making, and Business Development

Session 14-1: Drug Discovery Integrative Services, Deal-Making, and Business DevelopmentTime: 10:55-12:10, November 6, 2011 (Sunday) Place: Rose 1 Hall, 5th Floor, SCEC

Session Chair Dr. Maosheng Duan, VP and Head of Medicinal Chemistry, HD Biosciences (China) Co., Ltd, China

10:55-11:20 Title: Powering Drug Discovery Innovation in China, the CrownBio StoryDr. Sam Lou, Vice President, Business Development in Greater China Crown Biowcience. Inc., USA

11:20-11:45 Title: Fill in Client’s Pipeline Gap with Medicinal Chemistry Service from HD BiosciencesDr. Maosheng Duan, VP and Head of Medicinal Chemistry, HD Biosciences (China) Co., Ltd, China

11:45-12:10 Title: The Collaboration Models for Integrated Services CROs to Support Drug DiscoveryDr. Chunlin Chen, CEO, Shanghai Medicilon Inc., China

Chapter 15: Drug Discovery R & D Management and Translational Medicine

Session 15-1: The Knowledge Management Process for Drug DiscoveryTime: 08:30-10:10, November 6, 2011 (Sunday) Place: Rose 2 Hall, 5th Floor, SCEC

Session Chair Dr. Raghu Raghavan, Partner and President, Therataxis LLC, USA

08:30-08:55 Title: Learning and Knowledge Management in the Safety ArenaDr. Paul Beninger, Vice President, Global Patient Safety, Genzyme, USA

08:55-09:20 Title: Delivering Therapy to Target: An Often Forgotten Chapter in Improving the Probability of Successful Drug DevelopmentDr. Raghu Raghavan, Partner and President, Therataxis LLC, USA

09:20-09:45 Title: Securing, Increasing and Catching Value in Translational Medicine A Case StudyDr. Bernd Eisele, CEO, Vakzine Projekt Management GmbH, Germany

09:45-10:10 Title: Graphical Representation of the Assessment of Inventive Step Using the Problem-Solution-Approach ( PSA )Dr. Joachim Stellmach, Directorate Advisor, European Patent Office, Germany

037


Session 15-2: Biomarkers & Translational MedicineTime: 10:30-11:45, November 6, 2011 (Sunday) Place: Rose 2 Hall, 5th Floor, SCEC

Session Chair Dr. Richard May, Associate Director - Research, MedImmune Ltd, UK

10:30-10:55 Title: Heterogeneity in Severe Asthma: Implications for Future TherapiesDr. Richard May, Associate Director - Research, MedImmune Ltd., UK

10:55-11:20 Title: Driving Improved Clinical Outcomes with the Power of Illumina Next Generation SequencingTechnologyDr. Vanessa Tyrrell, Business Manager, Diagnostics, Illumina, Japan

11:20-11:45 Title: More Efficient Drug Discovery Trials in Schizophrenia: Insights from 29 Placebo-ControlledRcts of Second-Generation Antipsychotics in the Newmeds RepositoryDr. Jonathan Rabinowitz, Professor, Bar Ilan University, Israel

Session 15-3: Anticancer Translational MedicineTime: 10:30-12:10, November 6, 2011 (Sunday) Place: Peony Hall, 5th Floor, SCEC

Session Chair Dr. Michael N. Liebman, President/Managing Director, Strategic Medicine, Inc, USA

10:30-10:55 Title: From Bedside to Bench to BedsideDr. Michael R. Briggs, Senior Director, Vertex Pharmaceuticals, Inc, USA

10:55-11:20 Title: Translational Research, Bedside-to-Bench-to Bedside: Modeling Breast CancerDr. Michael N. Liebman, Managing Director, Strategic Medicine, Inc and BV, USA

11:20-11:45 Title: BINET Business Intelligence for Social Network Analysis, Case Study in Healthcare FieldDr. Sabrina Molinaro, Head, Epidemiology and Health Research Department, Institute for ClinicalPhysiology, National Research Council, Italy

11:45-12:10 Title: Using Genetically Defined Cell Lines to Predict Resistance to Targeted Cancer Therapies inPatientsDr. Rob Howes, R & D Director, Horizon Discovery, UK

Special Symposia on Non-Human Drug Discovery

Special Symposia on Non-Human Drug DiscoveryTime: 08:30-09:20, November 6, 2011 (Sunday) Place: Rose 3 Hall, 5th Floor, SCEC

Session Chair Dr. Marcus Remmers, Head of Pharmaceutical R & D, Merial Limited, USA

08:30-08:55 Title: Animal Health Discovery and LicensingDr. Marcus Remmers, Head of Pharmaceutical R & D, Merial Limited, USA

08:55-09:20 Title: Control of Emerging Infectious Diseases: Novel Targets and Vaccine FormulationsDr. Andrew A. Potter, Director and CEO, Vaccine and Infectious Disease Organization, InternationalVaccine Centre, Canada

038


Poster Presentation Session

Poster Presentation SessionTime: 13:30-15:00, November 4, 2011 (Friday) Place: Room No. 9, 1st Floor, SCEC

Session Chair Dr. Fabio Fazzi, University of Bologna, Italy

13:30-13:45 Title: Non Inferiority TrialsDr. Fabio Fazzi, University of Bologna, Italy

13:45-14:00 Title: Improving Poor Orally Bioavailable Drugs by Sublingual Administration—Example with PropronololDr. Zhijun Wang, Research Associate, School of Pharmacy, Chinese University of Hong Kong, China

14:00-14:15 Title: Activators of MRP1 as Anti-cancer Agents Targeting Chemoresistant Cancer CellsMs. Doriane Lorendeau, Drug Resistance Mechanism and Modulation, University Lyon 1, France

14:15-14:30 Title: Treatment of Halogen Bonding by Current Biomolecular EmpiricalMr. Michal Kolar, Institute of Organic Chemistry and Biochemistry, Czech Republic

14:30-14:45 Title: Amelioration of Atopic Dermatitis Model in Mice by NF-B Inhibitor DHMEQ and its Mechanism of ActionMs. Kana Horie, Center for Chemical Biology, Faculty of Science and Technology, Keio University,Japan

14:45-15:00 Title: Isolation and Screening of Actinobacteria and Proteobacteria from Antarctic Soil for AntimicrobialMetabolitesMr. Lee Learn Han, Universiti Putra Malaysia, Malaysia

Documents

Drug Discovery Program- Shenzhen, China